Obesity’s Role in Cancer Risk May Be Substantially Underestimated

Overview

Obesity’s contribution to cancer risk is likely underestimated due to methodological limitations in epidemiologic studies, including prediagnostic weight loss and reliance on single-point BMI measurements. The PLUS framework identifies key factors biasing risk estimates downward, suggesting a larger impact of obesity on cancer development than previously recognized.

Background

Obesity is a known risk factor for various cancers, but its true impact may be obscured by how weight and adiposity are measured in research. Traditional reliance on body mass index (BMI) at a single time point and conventional BMI thresholds may fail to capture lifetime exposure and central obesity, which are important for cancer risk. Additionally, prediagnostic weight loss, especially in gastrointestinal cancers, can lead to underestimation of obesity’s role near diagnosis. Understanding these limitations is crucial for accurate risk assessment and effective cancer prevention strategies.

Data Highlights

Key Findings

• Prediagnostic weight loss in patients with gastrointestinal cancers leads to underestimation of BMI near diagnosis.
• Single-time-point BMI measurements do not reflect cumulative lifetime exposure to excess weight.
• Waist circumference may better capture cancer risk associated with visceral adiposity than BMI in some populations.
• Conventional BMI thresholds may miss cancer risk present below a BMI of 25.
• Adjusting for prediagnostic weight loss increased the estimated population-attributable fraction for obesity-related gastrointestinal cancers from 7% to 18% in UK Biobank data.
• Interventions such as bariatric surgery show mixed effects on cancer risk, with some procedures linked to reduced risk and others to increased colorectal cancer risk.

Clinical Implications

Clinicians should recognize that obesity’s impact on cancer risk is likely greater than current estimates suggest, emphasizing the importance of comprehensive weight history and central obesity measures in risk assessment. Integrating obesity control into cancer prevention frameworks could enhance public health outcomes. Further research is needed to clarify the benefits and risks of obesity interventions, including bariatric surgery and pharmacologic treatments.

Conclusion

The PLUS framework highlights critical biases that underestimate obesity’s role in cancer development, underscoring the need for refined measurement approaches and stronger integration of obesity control in cancer prevention strategies.

References

1. Luo et al., JAMA Oncology, 2024 -- Obesity’s Cancer Role Underestimated